Oncology · KRAS G12C-Positive Non-Small Cell Lung CancerTrial Updatecompetitivemid-term

Divarasib Study Targets KRAS G12C-Positive NSCLC Post-Chemoimmunotherapy

Importance8/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/12/2026, 6:31:42 AM

Assessment confidence: 75% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of divarasib against established immunotherapies could significantly alter treatment protocols for KRAS G12C-positive NSCLC. A successful outcome may enhance Hoffmann-La Roche's market position and influence competitive dynamics in oncology. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 17 ranked evidence items (11 high-relevance).

Strategic Assessment

Success in this trial could shift treatment paradigms and increase Hoffmann-La Roche's competitive edge in the NSCLC market. The strongest clinical anchor is A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel (ClinicalTrials.gov), sub-indication match (lung cancer); mechanism alignment (kras). In lung cancer, 4 regulatory and 3 competitive items passed relevance filtering for Roche.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial (Humanexa Signals) — sub-indication match (lung cancer); mechanism alignment (kras). Secondary pressure from Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial. This trial positions divarasib as a potential alternative to established therapies like pembrolizumab and nivolumab for KRAS G12C-positive NSCLC.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Sponsor/company relevance (Roche). Relevant agencies in corpus: MHRA, FDA. The trial results will be critical for future regulatory submissions and could influence labeling and treatment guidelines for KRAS G12C-positive NSCLC.

Key Risks

Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.
Signal severity is high — leadership review is warranted.

Key Opportunities

If divarasib proves effective, it could capture significant market share from existing therapies, potentially leading to increased revenues for Hoffmann-La Roche.
Upside for Roche may improve if A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · KRAS G12C NSCLC · Trial Update · Divarasib's positive results position it as a potential new standard of care, challenging the current market leaders sotorasib and adagrasib.
Lead sponsor: Janssen Research & Development, LLC.
Upside for Roche may improve if JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study (ClinicalTrials.gov) delivers favorable follow-through.

What Would Change This Assessment

This becomes more urgent if Monitor trial results and any updates on patient outcomes and safety profiles.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Withdrawn | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cel
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
FDA document
View source
Study of Amivantamab, Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study
ClinicalTrials.govhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM),
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
ClinicalTrials.govmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
ClinicalTrials.govlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Roche's Divarasib Shows Best-in-Class Potential in Phase III NSCLC Trial
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Mechanism alignment (KRAS)
Pfizer's LORBRENA CROWN Trial Reports Longest Progression-Free Survival in Advanced NSCLC
Humanexa Signalshigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Pfizer)

Inhibition of STAT3-mediated glycolysis by bruceine D suppresses non-small-cell lung cancer progression in vitro and in vivo.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
Microwave hyperthermia enhances radiosensitivity of highly invasive non-small cell lung cancer cells via inhibiting Sonic Hedgehog signaling pathway.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
CXCL13-expressing CD4(+) T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC.
PubMedhigh relevance
Sub-indication match (lung cancer); Sponsor/company relevance (Roche)
FDA document
View source
Single-cell sequencing profiling of intratumoral heterogeneity and immunosuppressive microenvironment in primary thyroid cancer and lymph node metastases.
PubMedlow relevance
Sponsor/company relevance (Roche)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Roche
Divarasib
Pembrolizumab
Nivolumab

Commercial impact

high

If divarasib proves effective, it could capture significant market share from existing therapies, potentially leading to increased revenues for Hoffmann-La Roche.

Regulatory impact

medium

The trial results will be critical for future regulatory submissions and could influence labeling and treatment guidelines for KRAS G12C-positive NSCLC.

What to watch

Monitor trial results and any updates on patient outcomes and safety profiles.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.